Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04742777 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function]

Study acronym: mTOR
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Sep 9, 2025 to Oct 16, 2026
    • Trial status: Completed to Active, Not Recruiting
    v14
  2. Trial status: Recruiting to Completedv13 Show 4 more changesShow less
    • Enrollment target: estimated 12 to confirmed 20
    • Primary completion date changed from estimate of Dec 2025 to Sep 9, 2025
    • Study completion date changed from estimate of Jun 2026 to Sep 9, 2025
    • Site details revised at 2 of 2 sites
  3. Eligibility criteria shortened, about 78 wordsv12
  4. Re-verified, no change to tracked fieldsv11
  5. Primary completion date: Dec 2024 to Dec 2025
    • Study completion date: Jun 2025 to Jun 2026
    v10
Show 8 earlier versionsHide 8 earlier versions
  1. Primary completion date: Dec 2023 to Dec 2024
    • Study completion date: Jun 2024 to Jun 2025
    v9
  2. Primary completion date: Dec 2024 to Dec 2023
    • Study completion date: Jun 2025 to Jun 2024
    v8
  3. Primary completion date: Dec 2023 to Dec 2024
    • Study completion date: Jun 2024 to Jun 2025
    v7
  4. Collaborators: 1 to 2v6
  5. Trial status: Not Yet Recruiting to Recruitingv5 Show 4 more changesShow less
    • Primary completion date: Dec 2022 to Dec 2023
    • Study completion date: Jun 2023 to Jun 2024
    • Start date changed from estimate of Dec 2021 to Feb 1, 2022
    • Site details revised at 2 of 2 sites
  6. Start date: Oct 2021 to Dec 2021v4
  7. Start date: Jul 2021 to Oct 2021v3
  8. Start date: Mar 2021 to Jul 2021v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The ability to mount an effective immune response declines with age, leaving the elderly increasingly susceptible to infectious diseases and cancer. Rapamycin, an FDA approved drug to prevent transplant rejection, increases the lifespan and healthspan of mice and ameliorates age-related declines in immune responsiveness, cancer survival, and cognition in laboratory animals. Investigators are conducting a translational trial to test whether rapamycin also improves life functions in humans focusing on elderly persons (aged 70-95). Substudy E will evaluate the Rapamycin and Cardiac Function.
Trial Details
NCT Number NCT04742777
Lead Sponsor The University of Texas Health Science Center at San Antonio
Collaborators: The Claude D. Pepper Older Americans Independence Centers, National Institute on Aging (NIA)
Conditions
(from sponsor)		 Aging
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov